Discover what’s new with CathWorks and the CathWorks FFRangio™ System.
Stay up-to-date on what‘s new.
Mar 04, 2019
CathWorks Appoints Chief Financial Officer
CathWorks announced that Mike Feher has joined CathWorks as Vice President of Finance and Chief Financial Officer. His appointment coincides with US commercialization of the CathWorks FFRangio™ System.
Feb 25, 2019
CathWorks Adds Vice President of Global Marketing to Leadership Team
CathWorks announced that Ramin Mousavi has joined as Vice President of Global Marketing & Strategy to take responsibility for the CathWorks FFRangio™ System U.S. clinical and commercial launch and direct future expansion into other global markets.
Feb 04, 2019
CathWorks Announces Completion Of $30 Million Financing
CathWorks announced the completion of a $30 million Series C financing round led by Deerfield Management.
Dec 27, 2018
CathWorks Names Paul Kapsner as Vice President of Sales
CathWorks announced that Paul Kapsner has been named as Global Vice President of Sales. His appointment coincides with recent United States FDA clearance of the company’s CathWorks FFRangio™ System.
Dec 20, 2018
CathWorks FFRangio™ System Receives U.S. FDA Clearance.
CathWorks announced today that its FFRangio™ System received United States Food & Drug Administration (FDA) 510(k) clearance. The FFRangio system demonstrated accuracy versus the invasive FFR wire in a blinded comparative study, FAST-FFR.
Sep 24, 2018
CathWorks FFRangio™ Trial Meets Primary Enpoint and Exceeds Performance Goals.
The journal Circulation published results from the CathWorks FFRangio™ FAST-FFR clinical trial in an article titled Accuracy of Fractional Flow Reserve Derived From Coronary Angiography.
Sep 12, 2018
CathWorks FFRangio™ System Clinical Review Featured in TCT 2018 Program.
The CathWorks FFRangio™ System will be featured in a TCT Lunch Presentation Theater Program held during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego.
Aug 29, 2018
FAST-FFR Pivotal Trial Added To TCT 2018 Late-Breaking Clinical Trial Program.
CathWorks announced that the FAST-FFR pivotal trial has been added to the late-breaking clinical science program during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego.
Aug 22, 2018
CathWorks FFRangio™ System files FDA 510(k) submission.
CathWorks announced that it has submitted its CathWorks FFRangio™ System to the United States Food & Drug Administration (FDA) for review and 510(k) market clearance.
Aug 15, 2018
CathWorks Fast-FFR trial enrollment completed early.
CathWorks announced that its FAST-FFR trial is fully enrolled ahead of schedule. The trial is designed to evaluate efficacy of the CathWorks FFRangio™ System in terms of sensitivity and specificity when compared to conventional invasive Fractional Flow Reserve (FFR).
Come and meet the CathWorks team at our various events and learn how the CathWorks FFRangio™ System can help you and your patients.